{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T15:22:17Z","timestamp":1790954537211,"version":"4.1.0"},"reference-count":43,"publisher":"Elsevier BV","issue":"34","license":[{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,6,22]],"date-time":"2021-06-22T00:00:00Z","timestamp":1624320000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100016302","name":"Coalition for Epidemic Preparedness Innovations","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016302","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1016\/j.vaccine.2021.06.057","type":"journal-article","created":{"date-parts":[[2021,6,23]],"date-time":"2021-06-23T11:53:25Z","timestamp":1624449205000},"page":"4885-4894","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"title":["One or two dose regimen of the SARS-CoV-2 synthetic DNA vaccine INO-4800 protects against respiratory tract disease burden in nonhuman primate challenge model"],"prefix":"10.1016","volume":"39","author":[{"given":"Karen E.","family":"Gooch","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trevor R.F.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco J.","family":"Salguero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan A.","family":"Fotheringham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3146-3457","authenticated-orcid":false,"given":"Robert J.","family":"Watson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mike J.","family":"Dennis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alastair","family":"Handley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2576-8502","authenticated-orcid":false,"given":"Holly E.","family":"Humphries","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Longet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom","family":"Tipton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Sarfas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Sibley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gillian S.","family":"Slack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Rayner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn A.","family":"Ryan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9232-1888","authenticated-orcid":false,"given":"Katherine","family":"Schultheis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5326-4937","authenticated-orcid":false,"given":"Stephanie J.","family":"Ramos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9481-0079","authenticated-orcid":false,"given":"Andrew","family":"White","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0242-8524","authenticated-orcid":false,"given":"Sue","family":"Charlton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sally A.","family":"Sharpe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fergus","family":"Gleeson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent M.","family":"Humeau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8537-8920","authenticated-orcid":false,"given":"Yper","family":"Hall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kate E.","family":"Broderick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miles W.","family":"Carroll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2021.06.057_b0005","unstructured":"World Health, O., Coronavirus disease 2019 (COVID-19): situation report, 51. 2020, World Health Organization: Geneva."},{"issue":"8","key":"10.1016\/j.vaccine.2021.06.057_b0010","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1056\/NEJMoa2001017","article-title":"A Novel Coronavirus from Patients with Pneumonia in China, 2019","volume":"382","author":"Zhu","year":"2020","journal-title":"N Engl J Med"},{"issue":"7798","key":"10.1016\/j.vaccine.2021.06.057_b0015","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/s41586-020-2008-3","article-title":"A new coronavirus associated with human respiratory disease in China","volume":"579","author":"Wu","year":"2020","journal-title":"Nature"},{"issue":"35","key":"10.1016\/j.vaccine.2021.06.057_b0020","doi-asserted-by":"crossref","first-page":"E7348","DOI":"10.1073\/pnas.1707304114","article-title":"Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigen","volume":"114","author":"Pallesen","year":"2017","journal-title":"Proc Natl Acad Sci"},{"issue":"7592","key":"10.1016\/j.vaccine.2021.06.057_b0025","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1038\/nature17200","article-title":"Pre-fusion structure of a human coronavirus spike protein","volume":"531","author":"Kirchdoerfer","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2021.06.057_b0030","unstructured":"Muthumani, K., et al., A synthetic consensus anti\u2013spike protein DNA vaccine induces protective immunity against Middle East respiratory syndrome coronavirus in nonhuman primates. Sci Translational Med 2015. 7(301): p. 301ra132\u2013301ra132."},{"key":"10.1016\/j.vaccine.2021.06.057_b0035","article-title":"Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine","author":"Baden","year":"2020","journal-title":"N Engl J Med"},{"issue":"27","key":"10.1016\/j.vaccine.2021.06.057_b0040","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"New England J Med"},{"key":"10.1016\/j.vaccine.2021.06.057_b0045","doi-asserted-by":"crossref","unstructured":"Kremsner, P., et al., Phase 1 Assessment of the Safety and Immunogenicity of an mRNA- Lipid Nanoparticle Vaccine Candidate Against SARS-CoV-2 in Human Volunteers. medRxiv, 2020: p. 2020.11.09.20228551.","DOI":"10.1101\/2020.11.09.20228551"},{"key":"10.1016\/j.vaccine.2021.06.057_b0050","doi-asserted-by":"crossref","unstructured":"de Alwis, R., et al., A Single Dose of Self-Transcribing and Replicating RNA Based SARS-CoV-2 Vaccine Produces Protective Adaptive Immunity In Mice. bioRxiv, 2020: p. 2020.09.03.280446.","DOI":"10.1101\/2020.09.03.280446"},{"key":"10.1016\/j.vaccine.2021.06.057_b0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2020.100689","article-title":"Safety and immunogenicity of INO-4800 DNA vaccine against SARS-CoV-2: A preliminary report of an open-label, Phase 1 clinical trial","volume":"31","author":"Tebas","year":"2021","journal-title":"EClinicalMedicine"},{"issue":"1","key":"10.1016\/j.vaccine.2021.06.057_b0065","doi-asserted-by":"crossref","first-page":"2601","DOI":"10.1038\/s41467-020-16505-0","article-title":"Immunogenicity of a DNA vaccine candidate for COVID-19","volume":"11","author":"Smith","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.vaccine.2021.06.057_b9000","doi-asserted-by":"crossref","unstructured":"Gary, E.N., et al., A novel mouse AAV6 hACE2 transduction model of wild-type SARS-CoV-2 infection studied using synDNA immunogensGary, Ebony N. et al. iScience, 2021. Volume 24, Issue 7, 102699.","DOI":"10.1016\/j.isci.2021.102699"},{"key":"10.1016\/j.vaccine.2021.06.057_b0070","doi-asserted-by":"crossref","unstructured":"Patel, A., et al., Intradermal-delivered DNA vaccine provides anamnestic protection in a rhesus macaque SARS-CoV-2 challenge model. bioRxiv, 2020: p. 2020.07.28.225649.","DOI":"10.1101\/2020.07.28.225649"},{"key":"10.1016\/j.vaccine.2021.06.057_b0075","unstructured":"Salguero, F.J., White, A.D., Slack, G.S. et al. Comparison of rhesus and cynomolgus macaques as an infection model for COVID-19. Nat Commun 12, 1260 (2021)."},{"key":"10.1016\/j.vaccine.2021.06.057_b0080","doi-asserted-by":"crossref","unstructured":"Mu\u00f1oz-Fontela, C., et al., Animal models for COVID-19. Nature, 2020. 586(7830): p. 509\u2013515.","DOI":"10.1038\/s41586-020-2787-6"},{"issue":"6","key":"10.1016\/j.vaccine.2021.06.057_b0090","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1089\/hgtb.2014.061","article-title":"Direct transfection of dendritic cells in the epidermis after plasmid delivery enhanced by surface electroporation","volume":"25","author":"Amante","year":"2014","journal-title":"Hum Gene Ther Methods"},{"issue":"4","key":"10.1016\/j.vaccine.2021.06.057_b0095","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1089\/hgtb.2015.020","article-title":"Skin Transfection Patterns and Expression Kinetics of Electroporation-Enhanced Plasmid Delivery Using the CELLECTRA-3P, a Portable Next-Generation Dermal Electroporation Device","volume":"26","author":"Amante","year":"2015","journal-title":"Hum Gene Ther Methods"},{"key":"10.1016\/j.vaccine.2021.06.057_b0100","doi-asserted-by":"crossref","unstructured":"Diehl, M.C., et al., Tolerability of intramuscular and intradermal delivery by CELLECTRA((R)) adaptive constant current electroporation device in healthy volunteers. Hum Vaccin Immunother, 2013. 9(10): p. 2246\u201352.","DOI":"10.4161\/hv.24702"},{"issue":"3","key":"10.1016\/j.vaccine.2021.06.057_b0105","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1093\/infdis\/jiz132","article-title":"Intradermal SynCon(R) Ebola GP DNA Vaccine Is Temperature Stable and Safely Demonstrates Cellular and Humoral Immunogenicity Advantages in Healthy Volunteers","volume":"220","author":"Tebas","year":"2019","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2021.06.057_b0110","doi-asserted-by":"crossref","unstructured":"De Rosa, S.C., et al., Robust antibody and cellular responses induced by DNA-only vaccination for HIV. JCI Insight, 2020. 5(13).","DOI":"10.1172\/jci.insight.137079"},{"key":"10.1016\/j.vaccine.2021.06.057_b0115","doi-asserted-by":"crossref","unstructured":"Mammen, M.P., et al., Safety and immunogenicity of INO-4800 DNA vaccine against SARS-CoV-2: a preliminary report of a randomized, blinded, placebo-controlled, Phase 2 clinical trial in adults at high risk of viral exposure. 2021: p. 2021.05.07.21256652.","DOI":"10.1101\/2021.05.07.21256652"},{"key":"10.1016\/j.vaccine.2021.06.057_b0120","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2020.102903","article-title":"SARS-CoV-2 detection in different respiratory sites: A systematic review and meta-analysis","volume":"59","author":"Mohammadi","year":"2020","journal-title":"EBioMedicine"},{"issue":"23","key":"10.1016\/j.vaccine.2021.06.057_b0125","doi-asserted-by":"crossref","first-page":"12201","DOI":"10.1128\/JVI.06048-11","article-title":"A double-inactivated severe acute respiratory syndrome coronavirus vaccine provides incomplete protection in mice and induces increased eosinophilic proinflammatory pulmonary response upon challenge","volume":"85","author":"Bolles","year":"2011","journal-title":"J Virol"},{"issue":"9","key":"10.1016\/j.vaccine.2021.06.057_b0130","doi-asserted-by":"crossref","first-page":"6337","DOI":"10.4049\/jimmunol.181.9.6337","article-title":"Prior Immunization with Severe Acute Respiratory Syndrome (SARS)-Associated Coronavirus (SARS-CoV) Nucleocapsid Protein Causes Severe Pneumonia in Mice Infected with SARS-CoV","volume":"181","author":"Yasui","year":"2008","journal-title":"J Immunol"},{"issue":"16","key":"10.1016\/j.vaccine.2021.06.057_b0135","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1056\/NEJMoa2024671","article-title":"Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates","volume":"383","author":"Corbett","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2021.06.057_b0140","unstructured":"Bewley, K.R., et al., Immunological and pathological outcomes of SARS-CoV-2 challenge after formalin-inactivated vaccine immunisation of ferrets and rhesus macaques. 2020: p. 2020.12.21.423746."},{"key":"10.1016\/j.vaccine.2021.06.057_b0145","doi-asserted-by":"crossref","unstructured":"Rauch, S., et al., mRNA vaccine CVnCoV protects non-human primates from SARS-CoV-2 challenge infection. bioRxiv, 2020: p. 2020.12.23.424138.","DOI":"10.1101\/2020.12.23.424138"},{"key":"10.1016\/j.vaccine.2021.06.057_b0150","unstructured":"Vogel, A., et al., A prefusion SARS-CoV-2 spike RNA vaccine is highly immunogenic and prevents lung infection in non-human primates. bioRxiv, 2020."},{"issue":"4","key":"10.1016\/j.vaccine.2021.06.057_b0155","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1038\/s41591-021-01294-w","article-title":"Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies","volume":"27","author":"Chen","year":"2021","journal-title":"Nat Med"},{"issue":"6538","key":"10.1016\/j.vaccine.2021.06.057_b0160","doi-asserted-by":"crossref","DOI":"10.1126\/science.abg3055","article-title":"Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England","volume":"372","author":"Davies","year":"2021","journal-title":"Science"},{"issue":"7858","key":"10.1016\/j.vaccine.2021.06.057_b0165","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/s41586-021-03426-1","article-title":"Increased mortality in community-tested cases of SARS-CoV-2 lineage B.1.1.7","volume":"593","author":"Davies","year":"2021","journal-title":"Nature"},{"issue":"9","key":"10.1016\/j.vaccine.2021.06.057_b0170","doi-asserted-by":"crossref","first-page":"2523","DOI":"10.1016\/j.cell.2021.04.006","article-title":"Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity","volume":"184","author":"Garcia-Beltran","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.vaccine.2021.06.057_b0175","doi-asserted-by":"crossref","unstructured":"Andrade, V.M., et al., INO-4800 DNA Vaccine Induces Neutralizing Antibodies and T cell Activity Against Global SARS-CoV-2 Variants. 2021: p. 2021.04.14.439719.","DOI":"10.1101\/2021.04.14.439719"},{"key":"10.1016\/j.vaccine.2021.06.057_b0180","doi-asserted-by":"crossref","unstructured":"Wu, K., et al., Preliminary Analysis of Safety and Immunogenicity of a SARS-CoV-2 Variant Vaccine Booster. 2021: p. 2021.05.05.21256716.","DOI":"10.1101\/2021.05.05.21256716"},{"key":"10.1016\/j.vaccine.2021.06.057_b0185","unstructured":"Reed, C.C., et al., Design and immunogenicity of a Pan-SARS-CoV-2 synthetic DNA vaccine. 2021: p. 2021.05.11.443592."},{"key":"10.1016\/j.vaccine.2021.06.057_b0190","doi-asserted-by":"crossref","DOI":"10.1038\/s41586-021-03594-0","article-title":"Neutralizing antibody vaccine for pandemic and pre-emergent coronaviruses","author":"Saunders","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2021.06.057_b0195","doi-asserted-by":"crossref","unstructured":"Wibmer, C.K., et al., SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma. 2021: p. 2021.01.18.427166.","DOI":"10.1101\/2021.01.18.427166"},{"key":"10.1016\/j.vaccine.2021.06.057_b0200","doi-asserted-by":"crossref","unstructured":"Moore, J.P, P.A. Offit. SARS-CoV-2 Vaccines and the Growing Threat of Viral Variants. JAMA, 2021.","DOI":"10.1001\/jama.2021.1114"},{"issue":"10","key":"10.1016\/j.vaccine.2021.06.057_b0205","doi-asserted-by":"crossref","first-page":"459","DOI":"10.5694\/mja2.50569","article-title":"Isolation and rapid sharing of the 2019 novel coronavirus (SARS-CoV-2) from the first patient diagnosed with COVID-19 in Australia","volume":"212","author":"Caly","year":"2020","journal-title":"Med J Aust"},{"issue":"1","key":"10.1016\/j.vaccine.2021.06.057_b0210","doi-asserted-by":"crossref","DOI":"10.1128\/JCM.00963-19","article-title":"Metagenomic Nanopore Sequencing of Influenza Virus Direct from Clinical Respiratory Samples","volume":"58","author":"Lewandowski","year":"2019","journal-title":"J Clin Microbiol"},{"issue":"7809","key":"10.1016\/j.vaccine.2021.06.057_b0215","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/s41586-020-2196-x","article-title":"Virological assessment of hospitalized patients with COVID-2019","volume":"581","author":"Wolfel","year":"2020","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.vaccine.2021.06.057_b0220","doi-asserted-by":"crossref","first-page":"5","DOI":"10.3390\/cells1010005","article-title":"ELISPOT Refinement Using Spot Morphology for Assessing Host Responses to Tuberculosis","volume":"1","author":"Sibley","year":"2012","journal-title":"Cells"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X21008070?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X21008070?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:59:51Z","timestamp":1759402791000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X21008070"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8]]},"references-count":43,"journal-issue":{"issue":"34","published-print":{"date-parts":[[2021,8]]}},"alternative-id":["S0264410X21008070"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2021.06.057","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2021,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"One or two dose regimen of the SARS-CoV-2 synthetic DNA vaccine INO-4800 protects against respiratory tract disease burden in nonhuman primate challenge model","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2021.06.057","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Crown Copyright \u00a9 2021 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}